Cris Niño Bon Marasigan

Dr. Cris Niño Bon Marasigan

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2026 in Metabolites
Verified
Journal Article
Open access
PDF file
TYTomohiro Yonezawa
Tomohiro Yonezawa
YLYixue Lei
Yixue Lei
CMCris Niño Bon Marasigan
Cris Niño Bon Marasigan
MKMao Komori
Mao Komori
NFNanasa Fujiwara
Nanasa Fujiwara
EKEiji Kobayashi
Eiji Kobayashi
Background/Objectives: Mandarin orange peel (MOP) is rich in bioactive polymethoxyflavones, including hesperidin and nobiletin, which have shown neuroprotective effects in rodent models. However, comprehensive safety data in dogs are required to support its development as a therapeutic intervention for canine cognitive dysfunction syndrome. In this study, the safety profile of a standardized MOP formulation was evaluated in four healthy Beagle dogs. Methods: Initially, compositional analysis was performed, and 202 pesticide residues and psoralens were screened to ensure compliance with Japanese pet food safety standards. Subsequently, a dose-escalation study was conducted in which dogs received oral MOP at 2, 6, and 10 g/head/day for 3–4 weeks at each dose level. Clinical signs, hematology, and serum biochemistry were monitored throughout the study period. Results: The MOP powder composition and residue levels remained within regulatory safety limits. In the dose-escalation study, no significant dose-dependent abnormalities were observed in physical or clinicopathological parameters. One dog exhibited transient loose stools at higher doses and a temporary elevation in alkaline phosphatase levels at 2 g/head/day; however, these symptoms resolved spontaneously despite continued administration. Conclusions: MOP was safe and well tolerated in dogs even at 10 g/head/day (787–952 mg/kg/day), which is approximately five times the anticipated clinical dose. The observed fluctuations in active ingredient concentrations remained within the acceptable range for natural products and did not affect overall safety. Combined with comprehensive screening for residues, these results indicate that MOP is a high-quality and safe dietary intervention for older dogs.

10 August 2026 in Veterinary Medicine and Science
Verified
Journal Article
Open access
PDF file
Takumi MatsuuraTakumi Matsuura
Takumi Matsuura
CMCris Niño Bon Marasigan
Cris Niño Bon Marasigan
TYTomohiro Yonezawa
Tomohiro Yonezawa
Objectives: This study aimed to establish an in vitro model of feline endothelial cells (FECs) undergoing apoptosis when cultured under various nutrient deprivation (starvation) conditions to investigate the protective effects of beraprost and its stereoisomers on endothelial cells. Methods: Various starvation conditions were tested to induce apoptosis in immortalized feline aortic endothelial cells as assessed by measuring caspase‐3/7 activity. The anti‐apoptotic effects of the racemic mixture of beraprost and the stereoisomers beraprost‐314d and beraprost‐315d contained in the racemic mixture were determined by measuring caspase‐3/7 activity and Bax / Bcl2 gene expression and performing the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. Results: Starvation significantly increased caspase‐3/7 activity and induced apoptosis in FECs. Beraprost and beraprost‐314d efficiently inhibited caspase‐3/7 activation in a dose‐dependent manner, whereas beraprost‐315d exhibited lower potency. Beraprost downregulated Bax expression and reduced the number of TUNEL‐positive cells, confirming its anti‐apoptotic effects. Conclusion and Relevance: Beraprost effectively attenuates starvation‐induced apoptosis‐associated events in cultured immortalized feline aortic endothelial cells, inhibits caspase‐3/7 activity, and modulates Bax expression. These findings suggest a potential hypothesized mechanism that may contribute to the clinical efficacy of beraprost observed in feline CKD, although further validation using renal endothelial cells and in vivo models is required.